Sarepta Therapeutics (SRPT) Amortizatization of Intangibles (2014 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Amortizatization of Intangibles of -$530000.0 for Q1 2026, up 72.28% year-over-year from -$307638.1 in Q1 2025, and down 39.47% quarter-over-quarter from -$380000.0 in Q4 2025.
Powered by 
Analysis
Sarepta Therapeutics (SRPT) Amortizatization of Intangibles (2014 - 2026) Analysis & Trends
Sarepta Therapeutics' Amortizatization of Intangibles history runs 9 years deep, the most recent figure standing at -$530000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles rose 72.28% year-over-year to -$530000.0; the TTM figure through Mar 2026 stood at -$3.9 million (up 86.88% YoY), while the FY2025 annual figure was -$5.3 million, up 86.86% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at -$530000.0, down from -$380000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was -$50000.0 in Q1 2022, with the low at -$13.3 million in Q4 2023.
- The 5-year median for Amortizatization of Intangibles is -$6.1 million (2022), against an average of -$6.1 million.
- The sharpest annual moves came in 2023 and 2025: Amortizatization of Intangibles slumped 17202.0% in 2023, then soared 94.41% in 2025.
- Sarepta Therapeutics' Amortizatization of Intangibles stood at -$6.1 million in 2022, then sank by 117.33% to -$13.3 million in 2023, then soared by 48.96% to -$6.8 million in 2024, then jumped by 94.41% to -$380000.0 in 2025, then sank by 39.47% to -$530000.0 in 2026.
- Business Quant data shows SRPT's Amortizatization of Intangibles at -$530000.0 in Q1 2026, -$380000.0 in Q4 2025, and -$1.1 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Sarepta Therapeutics | 2.36 Bn | 1.57 Bn | 251.87 Mn | -905,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -905,000.00 |
| Mar 31, 2026 | -530,000.00 |
| Dec 31, 2025 | -380,000.00 |
| Sep 30, 2025 | -1.13 Mn |
| Jun 30, 2025 | -1.87 Mn |
| Mar 31, 2025 | -1.91 Mn |
| Dec 31, 2024 | -6.80 Mn |
| Sep 30, 2024 | -10.62 Mn |
| Jun 30, 2024 | -10.46 Mn |
| Mar 31, 2024 | -12.40 Mn |
| Dec 31, 2023 | -13.33 Mn |
| Sep 30, 2023 | -12.60 Mn |
| Jun 30, 2023 | -11.59 Mn |
| Mar 31, 2023 | -8.65 Mn |
| Dec 31, 2022 | -6.13 Mn |
| Sep 30, 2022 | -3.06 Mn |
| Jun 30, 2022 | -1.41 Mn |
| Mar 31, 2022 | -50,000.00 |
| Jun 30, 2018 | 1.57 Mn |
| Mar 31, 2018 | 1.26 Mn |